Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials

R. Iacovelli, A. Altavilla, G. Procopio, S. Bracarda, M. Santoni, S. Cascinu, E. Cortesi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background:About 20% of patients with prostate cancer have an ECOG performance status (PS) ≥2 at diagnosis. We investigate if current treatment options for castration-resistant prostate cancer (CRPC) may decrease the risk of death even in patients with ECOG PS of 2.Methods:PubMed was reviewed for phase III randomized trials in patients with CRPC progressed after docetaxel chemotherapy. Characteristics of each study and the relative hazard ratio (HR) for overall survival and 95% confidence interval (CI) were collected. Summary HR was calculated using random-or fixed-effects models depending on the heterogeneity of included studies.Results:A total of 3,149 patients was available for meta-analysis. In the overall population, the experimental treatments decrease the risk of death by 31% (HR=0.69; 95% CI: 0.63-0.76; P

Original languageEnglish
Pages (from-to)323-327
Number of pages5
JournalProstate Cancer and Prostatic Diseases
Volume16
Issue number4
DOIs
Publication statusPublished - Dec 2013

Fingerprint

docetaxel
Castration
Meta-Analysis
Prostatic Neoplasms
Confidence Intervals
Therapeutics
PubMed
Drug Therapy
Survival
Population

Keywords

  • Abiraterone acetate
  • Cabazitaxel
  • Castration-resistant prostate cancer
  • Enzalutamide
  • Performance status
  • Second line

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials. / Iacovelli, R.; Altavilla, A.; Procopio, G.; Bracarda, S.; Santoni, M.; Cascinu, S.; Cortesi, E.

In: Prostate Cancer and Prostatic Diseases, Vol. 16, No. 4, 12.2013, p. 323-327.

Research output: Contribution to journalArticle

@article{4904d767ef5340f7ac19e4ad8eb07ff3,
title = "Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials",
abstract = "Background:About 20{\%} of patients with prostate cancer have an ECOG performance status (PS) ≥2 at diagnosis. We investigate if current treatment options for castration-resistant prostate cancer (CRPC) may decrease the risk of death even in patients with ECOG PS of 2.Methods:PubMed was reviewed for phase III randomized trials in patients with CRPC progressed after docetaxel chemotherapy. Characteristics of each study and the relative hazard ratio (HR) for overall survival and 95{\%} confidence interval (CI) were collected. Summary HR was calculated using random-or fixed-effects models depending on the heterogeneity of included studies.Results:A total of 3,149 patients was available for meta-analysis. In the overall population, the experimental treatments decrease the risk of death by 31{\%} (HR=0.69; 95{\%} CI: 0.63-0.76; P",
keywords = "Abiraterone acetate, Cabazitaxel, Castration-resistant prostate cancer, Enzalutamide, Performance status, Second line",
author = "R. Iacovelli and A. Altavilla and G. Procopio and S. Bracarda and M. Santoni and S. Cascinu and E. Cortesi",
year = "2013",
month = "12",
doi = "10.1038/pcan.2013.20",
language = "English",
volume = "16",
pages = "323--327",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials

AU - Iacovelli, R.

AU - Altavilla, A.

AU - Procopio, G.

AU - Bracarda, S.

AU - Santoni, M.

AU - Cascinu, S.

AU - Cortesi, E.

PY - 2013/12

Y1 - 2013/12

N2 - Background:About 20% of patients with prostate cancer have an ECOG performance status (PS) ≥2 at diagnosis. We investigate if current treatment options for castration-resistant prostate cancer (CRPC) may decrease the risk of death even in patients with ECOG PS of 2.Methods:PubMed was reviewed for phase III randomized trials in patients with CRPC progressed after docetaxel chemotherapy. Characteristics of each study and the relative hazard ratio (HR) for overall survival and 95% confidence interval (CI) were collected. Summary HR was calculated using random-or fixed-effects models depending on the heterogeneity of included studies.Results:A total of 3,149 patients was available for meta-analysis. In the overall population, the experimental treatments decrease the risk of death by 31% (HR=0.69; 95% CI: 0.63-0.76; P

AB - Background:About 20% of patients with prostate cancer have an ECOG performance status (PS) ≥2 at diagnosis. We investigate if current treatment options for castration-resistant prostate cancer (CRPC) may decrease the risk of death even in patients with ECOG PS of 2.Methods:PubMed was reviewed for phase III randomized trials in patients with CRPC progressed after docetaxel chemotherapy. Characteristics of each study and the relative hazard ratio (HR) for overall survival and 95% confidence interval (CI) were collected. Summary HR was calculated using random-or fixed-effects models depending on the heterogeneity of included studies.Results:A total of 3,149 patients was available for meta-analysis. In the overall population, the experimental treatments decrease the risk of death by 31% (HR=0.69; 95% CI: 0.63-0.76; P

KW - Abiraterone acetate

KW - Cabazitaxel

KW - Castration-resistant prostate cancer

KW - Enzalutamide

KW - Performance status

KW - Second line

UR - http://www.scopus.com/inward/record.url?scp=84887609351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887609351&partnerID=8YFLogxK

U2 - 10.1038/pcan.2013.20

DO - 10.1038/pcan.2013.20

M3 - Article

VL - 16

SP - 323

EP - 327

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 4

ER -